Test targeted drugs to help radioactive iodine reach thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have differentiated thyroid cancer confirmed by pathology (biopsy/surgery tissue test)
- Your tumor has a specific target found on lab testing (NTRK, RET, ALK, BRAF, or another targetable change)
- Your CT scan shows lung metastases, such as many small solid nodules or growing discrete nodules
- You are starting an oncogene-specific targeted therapy (or already started) using a plan from a doctor or another approved trial access pathway
- You can get a whole-body thyroid scan without needing sedation or general anesthesia
- You are not pregnant or breastfeeding (because the scan uses radioactive iodine)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
This trial tests if a standard radioactive iodine treatment can help people with a type of thyroid cancer (called differentiated thyroid cancer) who have signs of the disease returning after their first treatment. It aims to see if this treatment can control the cancer and improve outcomes.
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.
Hear when a new Papillary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.